KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Capital Expenditures (2018 - 2025)

Castle Biosciences (CSTL) has disclosed Capital Expenditures for 8 consecutive years, with $6.9 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 538.92% to $6.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.3 million through Dec 2025, changed N/A year-over-year, with the annual reading at $11.3 million for FY2025, N/A changed from the prior year.
  • Capital Expenditures hit $6.9 million in Q4 2025 for Castle Biosciences, up from -$2.4 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $12.7 million in Q4 2023 to a low of -$12.8 million in Q3 2024.
  • Historically, Capital Expenditures has averaged $1.7 million across 5 years, with a median of $1.7 million in 2022.
  • Biggest five-year swings in Capital Expenditures: crashed 882.89% in 2021 and later soared 730.35% in 2023.
  • Year by year, Capital Expenditures stood at $3.3 million in 2021, then skyrocketed by 36.68% to $4.5 million in 2022, then skyrocketed by 182.58% to $12.7 million in 2023, then plummeted by 112.34% to -$1.6 million in 2024, then skyrocketed by 538.92% to $6.9 million in 2025.
  • Business Quant data shows Capital Expenditures for CSTL at $6.9 million in Q4 2025, -$2.4 million in Q3 2025, and $2.1 million in Q2 2025.